Calixa Initiates Phase 2 Clinical Trial For UTI

Calixa has initiated a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections (UTI). CXA-101 is a parenteral cephalosporin antibiotic with in-vitro and in-vivo activity against Pseudomonas aeruginosa, including drug resistant isolates.

Calixa is investigating CXA-101 as a potential treatment for serious bacterial infections in hospitalized patients.

The multi-center, randomized study is expected to enroll approximately 120 patients, and will compare the efficacy and safety of CXA-101 with the current standard of therapy.

Ian Friedland, CMO of Calixa, said: “The preclinical and Phase 1 results to date are very promising and indicate that CXA-101 is well tolerated and has broad-spectrum antibacterial coverage, including potent activity against increasingly resistant gram-negative pathogens such as Pseudomonas aeruginosa .This Phase 2 study will generate important information on the safety and effectiveness of CXA-101 in complicated urinary tract infections, which are usually caused by gram-negative pathogens.